October 10, 2024 SAN CARLOS, Calif., October 10, 2024 – Glycomine, Inc., a clinical-stage biotechnology company focused on developing new therapies for serious unserved orphan diseases, today announced the appointment of Joshua Grass as Chairperson of the Board. Mr. Grass succeeds Christopher Starr, Ph.D., who will continue to support the company as a scientific and clinical…
View detailsFebruary 25, 2022 — February 27, 2022 https://www.glycomine.com/news/events We proudly invite you to the 2022 Sanford Burnham Prebys Rare Disease Day Symposium & CDG/NGLY1 Family Conference, February 25-27, 2022 in San Diego, CA. The 2022 event is co-organized by Sanford Burnham Prebys and CDG CARE. The objective of this Conference is to combine patient-centered science and…
View detailsMarch 1, 2024 — March 3, 2024 https://www.glycomine.com/news/events In 2024, in partnership with CDG CARE and the Sanford Children’s Health Research Center, the Sanford Burnham Prebys Rare Disease Day Symposium will continue to focus on Congenital Disorders of Glycosylation “CDG Models and Therapy”. Researchers, clinicians, patients, family members, industry experts, and inspirational advocates will bring…
View detailsDec 3, 2024 2:35 PM EST 7th Annual Evercore ISI HealthCONx Conference
View details2024-12-11 Statistically significant difference in arrested disease in leriglitazone treated patients when compared to the natural history of the disease Submission of European marketing authorization application (MAA) for leriglitazone expected mid-2025. Barcelona, Spain and Düsseldorf, Germany – 11 December 2024 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central…
View details4 March 2025 Barcelona, Spain – 4 March 2025 – Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study has been dosed with leriglitazone. TREE is a phase 2a clinical study assessing the safety and efficacy…
View detailsNovember 12, 2024 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the third quarter ended September 30, 2024, and provided recent business highlights. “This is a transformative time for our Company, as we presented the first…
View detailsNovember 26, 2024 BOSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in a fireside chat at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 2:35 p.m. ET.…
View detailsFebruary 25, 2025 BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer, will participate in the following upcoming investor conferences: The live webcasts of both fireside chats will be available…
View detailsMarch 3, 2025 Aura will Participate in the Research Forum at the 40th Annual European Association of Urology Congress Aura will Host a Virtual Urologic Oncology Investor Event Featuring Key Opinion Leaders at 4:30 pm Eastern Time on March 24, 2025 BOSTON, March 03, 2025 (GLOBE NEWSWIRE) — Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to…
View details